Home›Articles›Sugemalimab: how a PD-L1 antibody was tested in two lung cancer settingsArticleSugemalimab: how a PD-L1 antibody was tested in two lung cancer settingsArticlesConnectionsSourcesComments (0)Reader Challenges (0)ConnectionsArticle OnSugemalimab, Drugs and Medicinal Substances Well-attested SourcesCejemly (EMA EPAR overview)Overview, What benefits of Cejemly have been shown in studies, locally advanced unresectable NSCLCQuote, Overview, What benefits of Cejemly have been shown in studies, locally advanced unresectable NSCLCResults showed no significant difference in survival between those who had the treatment and those who did not.View the SourceMedicine Atlas Original Articlestier 1Comments (0)No comments yet. Be the first to share a thought.Sign in to join the discussion.Reader Challenges (0)No disputes yet. Spotted an error or a better source? Open the first one.Sign in to dispute this or suggest a correction.